Aberg, A., Westbom, L., Källén, B. (2001). Congenital malformations among infants whose mothers had gestational diabetes or preexisting diabetes. Early Human Development, 61, 85–95.CrossRefGoogle ScholarPubMed

Adab, N., Kini, U., Vinten, J., et al. (2004). The longer term outcome of children born to mothers with epilepsy. J Neurol Neurosurg Psychiatry, 75, 1575–1583.CrossRefGoogle ScholarPubMed

Adedinsewo, D. A., Thurman, D. J., Luo, Y. H., et al. (2013). Valproate prescriptions for nonepilepsy disorders in reproductive-age women. Birth Defects Research Part A: Clinical and Molecular Teratology, 97, 403–408.Google Scholar

Aids Profile Summary. (2014). Pharm Med, 28, 265–271.CrossRefGoogle Scholar

Altshuler, L. L., Cohen, L., Szuba, M. P., et al. (1996). Pharmacologic management of psychiatric illness during pregnancy: dilemmas and guidelines. American Journal of Psychiatry, 153, 592–606.Google ScholarPubMed

American Academy of Pediatrics (2012). Breastfeeding and the use of human milk. Pediatrics, 129, e827–e841.Google Scholar

American College of Obstetricians and Gynecologists. (2008). ACOG Practice Bulletin: clinical management guidelines for obstetrician-gynecologists number 92, April 2008. Use of psychiatric medications during pregnancy and lactation. Obstetetrics and Gynecology, 111, 1001–1020.Google Scholar

Ban, L., West, J., Gibson, J. E., et al. (2014). First trimester exposure to anxiolytic and hypnotic drugs and the risks of major congenital anomalies: a United Kingdom population-based cohort study. PLoS One, 9(6), e100996. doi: 10.1371/journal.pone.0100996. eCollection 2014.Google Scholar

Barnes, T. R. (2011). Schizophrenia Consensus Group of British Association for Psychopharmacology. Evidence-based guidelines for the pharmacological treatment of schizophrenia: recommendations from the British Association for Psychopharmacology. J Psychopharmacol, 25, 567–620.Google Scholar

Bech, B. H., Kjaersgaard, M. I., Pedersen, H. S., et al. (2014). Use of antiepileptic drugs during pregnancy and risk of spontaneous abortion and stillbirth: population based cohort study. BMJ, 349, g5159. doi: 10.1136/bmj.g5159.CrossRefGoogle ScholarPubMed

Bennett, P. N. (1996). Use of monographs in drugs. In: Bennett, P. N. (Ed.), Drugs and Human Lactation (pp. 67–74). Amsterdam: Elsevier Science Publishers.Google Scholar

Bodén, R., Lundgren, M., Brandt, L., et al. (2012a). Risks of adverse pregnancy and birth outcomes in women treated or not treated with mood stabilisers for bipolar disorder: population based cohort study. BMJ, 345, e7085. doi: 10.1136/bmj.e7085.Google Scholar

Bodén, R., Lundgren, M., Brandt, L., et al. (2012b). Antipsychotics during pregnancy: relation to fetal and maternal metabolic effects. Arch Gen Psychiatry, 69: 715–721.Google Scholar

Bellantuono, C., Tofani, S., Di Sciascio, G., Santone, G. (2013). Benzodiazepine exposure in pregnancy and risk of major malformations: a critical overview. Gen Hosp Psychiatry, 35, 3–8.Google Scholar

Chad, L., Pupco, A., Bozzo, P., Koren, G. (2013). Update on antidepressant use during breastfeeding. Can Fam Physician, 59, 633–634.Google ScholarPubMed

Clark, E. C., Klein, A. M., Perel, J. M., et al. (2013). Lamotrigine dosing for pregnant patients with bipolar disorder. Am J Psychiatry, 170, 1240–1247.CrossRefGoogle ScholarPubMed

Christensen, J., Grønborg, T. K., Sørensen, M. J., et al. (2013). Prenatal valproate exposure and risk of autism spectrum disorders and childhood autism. JAMA, 309, 1696–1703.Google Scholar

Clements, C. C., Castro, V. M., Blumenthal, S. R., et al. (2014). Prenatal antidepressant exposure is associated with risk for attention-deficit hyperactivity disorder but not autism spectrum disorder in a large health system. Mol Psychiatry, Aug 26, doi: 10.1038/mp.2014.90. [Epub ahead of print]Google Scholar

Cohen, M. J., Meador, K. J., Browning, N., et al. (2013). Fetal antiepileptic drug exposure: Adaptive and emotional/behavioral functioning at age 6 years. Epilepsy Behav, 29, 308–315.CrossRefGoogle Scholar

Croen, L. A., Grether, J. K., Yoshida, C. K., et al. (2011). Antidepressant use during pregnancy and childhood autism spectrum disorders. Arch Gen Psychiatry, 68, 1104–1112.Google Scholar

Dayan, J., Graignic-Philippe, R., Seligmann, C., Andro, G. (2011). Use of antipsychotics and breastfeeding. Current Women’s Health Reviews, 7, 37–45.Google Scholar

Deligiannidis, K. M., Byatt, N., Freeman, M. P. (2014). Pharmacotherapy for mood disorders in pregnancy: a review of pharmacokinetic changes and clinical recommendations for therapeutic drug monitoring. J Clin Psychopharmacol, 34, 244–255.Google Scholar

Dellicour, S., ter Kuile, F. O., Stergachis, A. (2008). Pregnancy exposure registries for assessing antimalarial drug safety in pregnancy in malaria-endemic countries. PLoS Med, 5(9):e187. doi: 10.1371/journal.pmed.0050187. Epub Sep 2008.Google Scholar

Dev, V. J., Krupp, P. (1995) Adverse event profile and safety of clozapine. Rev Contemp Pharmacother, 6, 197–208.Google Scholar

Diav-Citrin, O., Shechtman, S., Ornoy, S., et al. (2005). Safety of haloperidol and penfluridol in pregnancy: a multicenter, prospective, controlled study. J Clin Psychiatry, 66, 317–322.Google Scholar

Diav-Citrin, O., Shechtman, S., Tahover, E., et al. (2014). Pregnancy outcome following in utero exposure to lithium: a prospective, comparative, observational study. Am J Psychiatry, 171, 785–794.CrossRefGoogle ScholarPubMed

El Marroun, H., White, T. J., van der Knaap, N. J., et al. (2014). Prenatal exposure to selective serotonin reuptake inhibitors and social responsiveness symptoms of autism: population-based study of young children. Br J Psychiatry, 205, 95–102.Google Scholar

Enato, E., Moretti, M., Koren, G. (2011). The fetal safety of benzodiazepines: an updated meta-analysis. J Obstet Gynaecol Can, 33, 46–48.Google Scholar

Etemad, L., Mohammad, A., Mohammadpour, A. H. et al. (2013) Teratogenic effects of pregabalin in mice. Iran J Basic Med Sci, 16, 1065–1070.Google Scholar

European Medicines Agency, Pharmacovigilance and Risk Assessment Committee (2014). PRAC recommends strengthening the restrictions on the use of valproate in women and girls. www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2014/10/news_detail_002186.jsp&mid=WC0b01ac058004d5c1Google Scholar

Frey, B., Braegger, C. P., Ghelfi, D. (2002).Neonatal cholestatic hepatitis from carbamazepine exposure during pregnancy and breast feeding. Ann Pharmacother, 36, 644–647.Google Scholar

Gentile, S. (2008). Infant safety with antipsychotic therapy in breast-feeding: a systematic review. J Clin Psychiatry, 69, 666–673.Google Scholar

Gentile, S. (2010). Antipsychotic therapy during early and late pregnancy. A systematic review. Schizophr Bull, 36, 518–544.Google Scholar

Gilad, O., Merlob, P., Stahl, B., Klinger, G. (2011). Outcome of infants exposed to olanzapine during breastfeeding. Breastfeed Med, 6, 55–58.Google Scholar

Grigoriadis, S., VonderPorten, E. H., Mamisashvili, L., et al. (2013). Antidepressant exposure during pregnancy and congenital malformations: is there an association? A systematic review and meta-analysis of the best evidence. J Clin Psychiatry, 74(4), e293-308. doi: 10.4088/JCP.12r07966.Google Scholar

Grigoriadis, S., Vonderporten, E. H., Mamisashvili, L., et al. (2014). Prenatal exposure to antidepressants and persistent pulmonary hypertension of the newborn: systematic review and meta-analysis. BMJ, 348, f6932. doi: 10.1136/bmj.f6932.CrossRefGoogle ScholarPubMed

Habermann, F., Fritzsche, J., Fuhlbrück, F., et al. (2013). Atypical antipsychotic drugs and pregnancy outcome: a prospective, cohort study. J Clin Psychopharmacol, 33, 453–462.Google Scholar

Hale, T. (2012). Medications and mother’s milk. Amarillo: Hale Publishing.Google Scholar

Hiemke, C., Baumann, P., Bergemann, N. et al. (2011). AGNP Consensus Guidelines for Therapeutic Drug Monitoring in Psychiatry: Update 2011.Google Scholar

Hodge, L. S. and Tracy, T. S. (2007). Alterations in drug disposition during pregnancy: implications for drug therapy. Expert Opin Drug Metab Toxicol, 2007, 3, 557–571.Google Scholar

Huang, H., Coleman, S., Bridge, J. A., et al. (2014). A meta-analysis of the relationship between antidepressant use in pregnancy and the risk of preterm birth and low birth weight. Gen Hosp Psychiatry, 36, 13–8.CrossRefGoogle ScholarPubMed

Huybrechts, K. F., Sanghani, R. S., Avorn, J., Urato, A. C. (2014). Preterm birth and antidepressant medication use during pregnancy: a systematic review and meta-analysis. PLoS One, 9(3):e92778. doi: 10.1371/journal.pone.0092778. eCollection 2014.Google Scholar

Jentink, J., Loane, M. A., Dolk, H., et al. (2010a). Valproic acid monotherapy in pregnancy and major congenital malformations. N Engl J Med, 362, 2185–2193.Google Scholar

Jentink, J., Dolk, H., Loane, M. A., et al. (2010b). Intrauterine exposure to carbamazepine and specific congenital malformations: systematic review and case-control study. BMJ, 341:c6581. doi: 10.1136/bmj.c6581.CrossRefGoogle ScholarPubMed

Johnson, K. C., LaPrairie, J. L., Brennan, P. A., et al. (2012). Prenatal antipsychotic exposure and neuromotor performance during infancy. Arch Gen Psychiatry, 69, 787–794.Google Scholar

Källén, B., Borg, N. and Reis, M. (2013). The use of central nervous system active drugs during pregnancy. Pharmaceuticals (Basel), 6, 1221–1286.CrossRefGoogle ScholarPubMed

Källén, B. and Otterblad Olausson, P. (2006). Antidepressant drugs during pregnancy and infant congenital heart defect. Reprod Toxicol, 21, 221–222.Google Scholar

Källén, B. and Reis, M. (2012). Neonatal complications after maternal concomitant use of SSRI and other central nervous system active drugs during the second or third trimester of pregnancy. J Clin Psychopharmacol, 32, 608–614.Google Scholar

Kieviet, N., Dolman, K. M., and Honig, A. (2013). The use of psychotropic medication during pregnancy: how about the newborn? Neuropsychiatr Dis Treat, 9, 1257–1266.Google Scholar

Lact med, accessed October 19, 2014; http://toxnet.nlm.nih.gov/cgi-bin/sis/search2Google Scholar

Lin, H. C., Chen, I. J., Chen, Y. H., et al. (2010). Maternal schizophrenia and pregnancy outcome: does the use of antipsychotics make a difference? Schizophr Res, 116, 55–60.Google Scholar

Man, S. L., Petersen, I., Thompson, M., Nazareth, I. (2012). Antiepileptic drugs during pregnancy in primary care: a UK population based study. PLoS One, 7(12):e52339. doi: 10.1371/journal.pone.0052339. Epub Dec 18, 2012.CrossRefGoogle ScholarPubMed

Margulis, A. V., Kang, E. M., Hammad, T. A. (2014). Patterns of prescription of antidepressants and antipsychotics across and within pregnancies in a population-based UK cohort. Matern Child Health J, 18, 1742–1752.CrossRefGoogle Scholar

Matalon, S., Schechtman, S., Goldzweig, G., Ornoy, A. (2002). The teratogenic effect of carbamazepine: a meta-analysis of 1255 exposures. Reprod Toxicol, 16, 9–17.Google Scholar

McKnight, R. F., Adida, M., Budge, K., et al. (2012). Lithium toxicity profile: a systematic review and meta-analysis. Lancet, 379, 721–728.Google Scholar

Meador, K., Reynolds, M. W., Crean, S., et al. (2008). Pregnancy outcomes in women with epilepsy: a systematic review and meta-analysis of published pregnancy registries and cohorts. Epilepsy, 81, 1–13.Google ScholarPubMed

Meador, K. J., Baker, G. A., Browning, N., et al. (2013). Fetal antiepileptic drug exposure and cognitive outcomes at age 6 years (NEAD study): a prospective observational study. Lancet Neurol, 12, 244–252.Google Scholar

Medicines and Health Care Products Regulatory Agency. (2011). Drug Safety Update, Sept 2011, vol. 5, issue 2: A2. www.mhra.gov.uk/home/groups/dsu/documents/publication/con129002.pdfGoogle Scholar

Moses-Kolko, E. L., Bogen, D., Perel, J., et al. (2005). Neonatal signs after late in utero exposure to serotonin reuptake inhibitors: literature review and implications for clinical applications. JAMA, 293, 2372–2383.Google Scholar

Myles, N., Newall, H., Ward, H., Large, M. (2013). Systematic meta-analysis of individual selective serotonin reuptake inhibitor medications and congenital malformations. Aust NZ J Psychiatry, 47, 1002–1012.Google Scholar

National Institute for Care and Health Excellence (2014). Antenatal and postnatal mental health – Clinical management and service guidance. Full guideline. NICE clinical guideline 192.Google Scholar

Newham, J. J., Thomas, S. H., MacRitchie, K., et al. (2008). Birth weight of infants after maternal exposure to typical and atypical antipsychotics: prospective comparison study. Br J Psychiatry, 192, 333–337.Google Scholar

Newport, D. J., Calamaras, M. R., DeVane, C. L., et al. (2007). Atypical antipsychotic administration during late pregnancy: placental passage and obstetrical outcomes. Am J Psychiatry, 164, 1214–1220.Google Scholar

Newport, D. J., Viguera, A. C., Beach, A. J., et al. (2005). Lithium placental passage and obstetrical outcome: implications for clinical management during late pregnancy. Am J Psychiatry, 162, 2162–2170.Google Scholar

Newport, D. J., Pennell, P. B., Calamaras, B. S., et al (2008). Lamotrigine in breast milk and nursing infants: determination of exposure. Pediatrics, 122, e223–e231.Google Scholar

Nulman, I., Koren, G., Rovet, J., et al. (2012). Neurodevelopment of children following prenatal exposure to venlafaxine, selective serotonin reuptake inhibitors, or untreated maternal depression. Am J Psychiatry, 169, 1165–1174.Google Scholar

Ohman, I., Vitols, S., Tomson, T. (2000). Lamotrigine in pregnancy: pharmacokinetics during delivery, in the neonate, and during lactation. Epilepsia, 41, 709–713.Google Scholar

Owens, L. A., O’Sullivan, E. P., Kirwan, B., et al. (2010). ATLANTIC DIP: the impact of obesity on pregnancy outcome in glucose-tolerant women. Diabetes Care, 33, 577–579.CrossRefGoogle ScholarPubMed

Palmsten, K., Hernández-Díaz, S., Huybrechts, K. F., et al. (2013). Use of antidepressants near delivery and risk of postpartum hemorrhage: cohort study of low income women in the United States. BMJ, 347, f4877. doi: 10.1136/bmj.f4877.Google Scholar

Peng, M., Gao, K., Ding, Y., et al. (2013). Effects of prenatal exposure to atypical antipsychotics on postnatal development and growth of infants: a case-controlled, prospective study. Psychopharmacology (Berl), 228, 577–584.Google Scholar

Pennell, P. B., Peng, L., Newport, D. J., et al. (2008). Lamotrigine in pregnancy: clearance, therapeutic drug monitoring, and seizure frequency. Neurology, 70, 2130–2136.CrossRefGoogle ScholarPubMed

Perucca, E., Battino, D., Tomson, T. (2014). Gender issues in antiepileptic drug treatment. Neurobiol Dis, 72 Pt B, 217–223.CrossRefGoogle ScholarPubMed

Petersen, I., McCrea, R. L., Osborn, D. J., et al. (2014). Discontinuation of antipsychotic medication in pregnancy: A cohort study. Schizophr Res, 159, 218–225.Google Scholar

Rai, D., Lee, B. K., Dalman, C., et al. (2013). Parental depression, maternal antidepressant use during pregnancy, and risk of autism spectrum disorders: population based case-control study. BMJ, 346, f2059. doi: 10.1136/bmj.f2059.Google Scholar

Reis, M. and Källén, B. (2008). Maternal use of antipsychotics in early pregnancy and delivery outcome. J Clin Psychopharmacol, 28, 279–288.Google Scholar

Reis, M. and Källén, B. (2010). Delivery outcome after maternal use of antidepressant drugs in pregnancy: an update using Swedish data. Psychol Med, 40, 1723–1733.Google Scholar

Rummel-Kluge, C., Komossa, K., Schwarz, S., et al. (2010). Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis. Schizophr Res, 123, 225–233.Google Scholar

Schou, M. (1976). What happened later to the lithium babies? A follow-up study of children born without malformations. Acta Psychiatr Scand, 54, 193–197.Google Scholar

Schou, M., Amdisen, A., Steenstrup, O. R. (1973). Lithium and pregnancy. II. Hazards to women given lithium during pregnancy and delivery. Br Med J, 2(5859), 137–138.CrossRefGoogle ScholarPubMed

Sebire, N. J., Jolly, M., Harris, J. P., et al. (2001). Maternal obesity and pregnancy outcome: a study of 287,213 pregnancies in London. Int J Obes Relat Metab Disord, 25, 1175–1182.Google Scholar

Slone, D., Siskind, V., Heinonen, O. P., et al. (1977). Antenatal exposure to the phenothiazines in relation to congenital malformations, perinatal mortality rate, birth weight, and intelligence quotient score. Am J Obstet Gynecol, 128, 486–488.Google Scholar

Sørensen, M. J., Grønborg, T. K., Christensen, J., et al. (2013). Antidepressant exposure in pregnancy and risk of autism spectrum disorders. Clin Epidemiol, 5, 449–459.Google Scholar

Teoh, S., Ilett, K. F., Hackett, L. P., Kohan, R. (2011). Estimation of rac-amisulpride transfer into milk and of infant dose via milk during its use in a lactating woman with bipolar disorder and schizophrenia. Breastfeed Med, 6, 85–88.Google Scholar

Toh, S., Li, Q., Cheetham, T. C., et al. (2013). Prevalence and trends in the use of antipsychotic medications during pregnancy in the U.S., 2001–2007: a population-based study of 585,615 deliveries. Arch Womens Ment Health, 16, 149–157.Google Scholar

Toh, S., Mitchell, A. A., Louik, C., et al. (2009). Selective serotonin reuptake inhibitor use and risk of gestational hypertension. Am J Psychiatry, 166, 320–328.Google Scholar

Tomson, T. (2005). Gender aspects of pharmacokinetics of new and old AEDs: pregnancy and breastfeeding. Ther Drug Monit, 27, 718–721.Google Scholar

Tomson, T., Battino, D. (2012). Teratogenic effects of antiepileptic drugs. Lancet Neurol, 11, 803–813.Google Scholar

Tomson, T., Landmark, C. J., Battino, D. (2013). Antiepileptic treatment in pregnancy: changes in drug disposition and their clinical implications. Epilepsia, 54, 405–414.Google Scholar

US Food and Drug Administration. (2011). FDA Drug Safety Communication: Antipsychotic drug labels updated on use during pregnancy and risk of abnormal muscle movements and withdrawal symptoms in newborns. www.fda.gov/drugs/drugsafety/ucm243903.htm.Google Scholar

Walsh-Sukys, M. C., Tyson, J. E., Wright, L. L., et al. (2000). Persistent pulmonary hypertension of the newborn in the era before nitric oxide: practice variation and outcomes. Pediatrics, 105(1 Pt 1), 14–20.Google Scholar

Weissman, A. M., Levy, B. T., Hartz, A. J., et al (2004). Pooled analysis of antidepressant levels in lactating mothers, breast milk, and nursing infants. Am J Psychiatry, 161, 1066–1078.Google Scholar

Wieck, A. (2011). The use of anti-epileptic medication in women with affective disorders in early and late pregnancy and during breastfeeding. Current Women’s Health Reviews, 7, 50–57.Google Scholar

Wikner, B. N., Källén, B. (2011). Are hypnotic benzodiazepine receptor agonists teratogenic in humans? J Clin Psychopharmacol, 31, 356–359.Google Scholar

Windhager, E., Kim, S. W., Saria, A., et al. (2014). Perinatal use of aripiprazole: plasma levels, placental transfer, and child outcome in 3 new cases. J Clin Psychopharmacol, 34, 637–641.Google Scholar

Wlodarczyk, B. J., Palacios, A. M., George, T. M., et al. (2012). Antiepileptic drugs and pregnancy outcomes. Am J Med Genet A, 158A(8): 2071–2090.Google Scholar

World Health Organization. (2013). Global Strategy for Infant and Young Child Feeding. ISBN 92 4 156221 8. Accessible at: www.who.int/nutrition/publications/infantfeeding/9241562218/en/.Google Scholar